
Get exclusive money-saving offers and guides
Straight to your inbox
Updated
We’re reader-supported and may be paid when you visit links to partner sites. We don’t compare all products in the market, but we’re working on it!
Universal Biosensors, Inc is a medical devices business based in Australia. Universal Biosensors shares (UBI) are listed on the Australian Securities Exchange (ASX) and all prices are listed in Australian Dollars. Universal Biosensors has a trailing 12-month revenue of around $4 million..
Our top pick for
US stocks
Our top pick for
Cheap broker fees
Our top pick for
Long-term investing
Since the stock market crash in March caused by coronavirus, Universal Biosensors's share price has had significant positive movement.
Its last market close was $0.32, which is 45.31% up on its pre-crash value of $0.175 and 146.15% up on the lowest point reached during the March crash when the shares fell as low as $0.13.
If you had bought $1,000 worth of Universal Biosensors shares at the start of February 2020, those shares would have been worth $777.78 at the bottom of the March crash, and if you held on to them, then as of the last market close they'd be worth $1,777.78.
52-week range | $0.13 - $0.345 |
---|---|
50-day moving average | $0.3084 |
200-day moving average | $0.2457 |
Target price | $0.51 |
PE ratio | 0.9635 |
Dividend yield | N/A (0%) |
Earnings per share (TTM) | $0.192 |
Standard brokerage - Australian shares
Competitive broker fees on Australian and international shares
Important: Share trading carries risk of capital loss.
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
Historical closes compared with the close of A$0.32 on 2020-10-22
1 week (2021-01-12) | -43.86% |
---|---|
1 month (2020-12-18) | -20.00% |
3 months (2020-10-19) | -1.54% |
6 months (2020-07-17) | 45.45% |
1 year (2020-01-17) | 82.86% |
---|---|
2 years (2019-01-18) | 45.45% |
3 years (2018-01-19) | 18.52% |
5 years (2016-01-19) | -28.89% |
Valuing Universal Biosensors stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of Universal Biosensors's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.
Universal Biosensors's current share price divided by its per-share earnings (EPS) over a 12-month period gives a "trailing price/earnings ratio" of roughly 1x. In other words, Universal Biosensors shares trade at around 1x recent earnings.
That's relatively low compared to, say, the P/E ratio for the ASX over the 12 months to December 2019 (32.14). The low P/E ratio could mean that investors are pessimistic about the outlook for the shares or simply that they're under-valued.
Universal Biosensors's EBITDA (earnings before interest, taxes, depreciation and amortisation) is $41.9 million (£0.0 million).
The EBITDA is a measure of a Universal Biosensors's overall financial performance and is widely used to measure a its profitability.
Revenue TTM | $4 million |
---|---|
Gross profit TTM | $3.3 million |
Return on assets TTM | -12.18% |
Return on equity TTM | -13.38% |
Profit margin | -147.35% |
Book value | 0.231 |
Market capitalisation | $55 million |
TTM: trailing 12 months
We're not expecting Universal Biosensors to pay a dividend over the next 12 months.
Over the last 12 months, Universal Biosensors's shares have ranged in value from as little as $0.13 up to $0.345. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (AU average) beta is 1, while Universal Biosensors's is 0.6151. This would suggest that Universal Biosensors's shares are less volatile than average (for this exchange).
Universal Biosensors, Inc., through its subsidiary, Universal Biosensors Pty Ltd, designs and develops electrochemical cells in Australia. The company focuses on the research, development, and manufacture of medical or testing devices. It uses electrochemical cell technology platform to develop point of use devices for various industries, including healthcare, food and drink, and agriculture. The company offers prothrombin time international normalized ratio coagulation test strips; and coagulation testing and calibration services, as well as distributes Siemens' Xprecia Stride Coagulation Analyzer. It also owns, operates, and manages a hemostasis laboratory. The company was founded in 2001 and is based in Rowville, Australia.
Steps to owning and managing Vanguard Australian Fixed Interest Index ETF units.
Steps to owning and managing Vanguard Ethically Conscious Global Aggregate Bond Index (Hedged) ETF units.
Steps to owning and managing ETFS Morningstar Global Technology ETF units.
Steps to owning and managing BetaShares Global Quality Leaders (Currency Hedged) ETF units.
Steps to owning and managing ETFS ROBO Global Robotics and Automation ETF units.
Steps to owning and managing ETFS FANG+ ETF units.
Steps to owning and managing ETFS S&P Biotech ETF units.
Steps to owning and managing ETFS Reliance India Nifty 50 ETF units.
Steps to owning and managing BetaShares India Quality ETF units.